Literature DB >> 19144785

Prominent role of alpha3/alpha6beta2* nAChRs in regulating evoked dopamine release in primate putamen: effect of long-term nicotine treatment.

Xiomara A Perez1, Kathryn T O'Leary, Neeraja Parameswaran, J Michael McIntosh, Maryka Quik.   

Abstract

Brain dopaminergic systems are critical in motor control as evidenced by findings that their disruption results in movement disorders such as Parkinson's disease. Nicotinic acetylcholine receptor (nAChR) activation plays an important role in regulating striatal dopaminergic function. Rodent studies show that short-term nicotine exposure influences stimulated striatal dopamine release with responsiveness dependent on neuronal activity. However, studies have not yet been done in nonhuman primates, nor has work been done to evaluate the effect of long-term nicotine exposure, which is relevant for therapies for chronic neurological disorders. Here, we used voltammetry to assess the role of nAChRs on evoked dopamine release from monkey putamen slices. In both ventral and dorsal putamen, alpha3/alpha6beta2(*) nAChRs regulated > or =80% of non-burst- (single pulse) nAChR-modulated dopamine release, and alpha4beta2(*) nAChRs regulated the remainder. Similar results were observed with burst-firing in ventral but not dorsal putamen, indicating that nAChR-modulated effects on release depend on the subregion and firing frequency. Next, we investigated the consequence of long-term nicotine exposure via the drinking water on nAChR-modulated responsiveness. Nicotine treatment altered both non-burst- and burst-stimulated dopamine release in ventral but not dorsal putamen. Altogether, these data support a predominant role for alpha3/alpha6beta2(*) nAChRs in the regulation of evoked dopamine release in nonhuman primate putamen. They also show that long-term nicotine treatment selectively modifies nAChR-modulated release in distinct striatal subregions. These findings have implications for the development of treatments for addiction and neurological disorders with nAChR dysfunction.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19144785      PMCID: PMC2684934          DOI: 10.1124/mol.108.053801

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  40 in total

Review 1.  Desensitization of nicotinic ACh receptors: shaping cholinergic signaling.

Authors:  Rashid Giniatullin; Andrea Nistri; Jerrel L Yakel
Journal:  Trends Neurosci       Date:  2005-07       Impact factor: 13.837

2.  Increases in alpha4* but not alpha3*/alpha6* nicotinic receptor sites and function in the primate striatum following chronic oral nicotine treatment.

Authors:  Sarah E McCallum; Neeraja Parameswaran; Tanuja Bordia; Hong Fan; Rachel F Tyndale; J William Langston; J Michael McIntosh; Maryka Quik
Journal:  J Neurochem       Date:  2006-01-12       Impact factor: 5.372

3.  Roles of accessory subunits in alpha4beta2(*) nicotinic receptors.

Authors:  Alexandre Kuryatov; Jennifer Onksen; Jon Lindstrom
Journal:  Mol Pharmacol       Date:  2008-04-01       Impact factor: 4.436

Review 4.  Striatal alpha6* nicotinic acetylcholine receptors: potential targets for Parkinson's disease therapy.

Authors:  Maryka Quik; J Michael McIntosh
Journal:  J Pharmacol Exp Ther       Date:  2005-10-06       Impact factor: 4.030

5.  Chronic nicotine and mecamylamine treatment increase brain nicotinic receptor binding without changing alpha 4 or beta 2 mRNA levels.

Authors:  J R Pauly; M J Marks; S F Robinson; J L van de Kamp; A C Collins
Journal:  J Pharmacol Exp Ther       Date:  1996-07       Impact factor: 4.030

6.  Long-term nicotine treatment decreases striatal alpha 6* nicotinic acetylcholine receptor sites and function in mice.

Authors:  Albert Lai; Neeraja Parameswaran; Mirium Khwaja; Paul Whiteaker; Jon M Lindstrom; Hong Fan; J Michael McIntosh; Sharon R Grady; Maryka Quik
Journal:  Mol Pharmacol       Date:  2005-01-28       Impact factor: 4.436

7.  Responses of midbrain dopamine neurons to behavioral trigger stimuli in the monkey.

Authors:  W Schultz
Journal:  J Neurophysiol       Date:  1986-11       Impact factor: 2.714

8.  Subunit composition of nicotinic receptors in monkey striatum: effect of treatments with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine or L-DOPA.

Authors:  Maryka Quik; Silvia Vailati; Tanuja Bordia; Jennifer M Kulak; Hong Fan; J Michael McIntosh; Francesco Clementi; Cecilia Gotti
Journal:  Mol Pharmacol       Date:  2004-10-06       Impact factor: 4.436

9.  Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens.

Authors:  Richard Exley; Michael A Clements; Henrike Hartung; J Michael McIntosh; Stephanie J Cragg
Journal:  Neuropsychopharmacology       Date:  2007-11-21       Impact factor: 7.853

10.  Non-agonist-binding subunit interfaces confer distinct functional signatures to the alternate stoichiometries of the alpha4beta2 nicotinic receptor: an alpha4-alpha4 interface is required for Zn2+ potentiation.

Authors:  Mirko Moroni; Ranjit Vijayan; Anna Carbone; Ruud Zwart; Philip C Biggin; Isabel Bermudez
Journal:  J Neurosci       Date:  2008-07-02       Impact factor: 6.167

View more
  27 in total

Review 1.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

2.  α6ß2* and α4ß2* nicotinic receptors both regulate dopamine signaling with increased nigrostriatal damage: relevance to Parkinson's disease.

Authors:  Xiomara A Perez; Tanuja Bordia; J Michael McIntosh; Maryka Quik
Journal:  Mol Pharmacol       Date:  2010-08-23       Impact factor: 4.436

3.  Repeated nicotine administration robustly increases bPiDDB inhibitory potency at alpha6beta2-containing nicotinic receptors mediating nicotine-evoked dopamine release.

Authors:  Andrew M Smith; Marharyta Pivavarchyk; Thomas E Wooters; Zhenfa Zhang; Guangrong Zheng; J Michael McIntosh; Peter A Crooks; Michael T Bardo; Linda P Dwoskin
Journal:  Biochem Pharmacol       Date:  2010-03-25       Impact factor: 5.858

Review 4.  Targeting nicotinic receptors for Parkinson's disease therapy.

Authors:  Maryka Quik; Tanuja Bordia; Luping Huang; Xiomara Perez
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

5.  Long-term nicotine treatment down-regulates α6β2* nicotinic receptor expression and function in nucleus accumbens.

Authors:  Xiomara A Perez; J Michael McIntosh; Maryka Quik
Journal:  J Neurochem       Date:  2013-10-13       Impact factor: 5.372

6.  Nicotinic receptors regulate the dynamic range of dopamine release in vivo.

Authors:  Jessica L Koranda; Jackson J Cone; Daniel S McGehee; Mitchell F Roitman; Jeff A Beeler; Xiaoxi Zhuang
Journal:  J Neurophysiol       Date:  2013-10-02       Impact factor: 2.714

Review 7.  Role of α6 nicotinic receptors in CNS dopaminergic function: relevance to addiction and neurological disorders.

Authors:  Maryka Quik; Xiomara A Perez; Sharon R Grady
Journal:  Biochem Pharmacol       Date:  2011-06-13       Impact factor: 5.858

Review 8.  Cholinergic interneurons in the dorsal and ventral striatum: anatomical and functional considerations in normal and diseased conditions.

Authors:  Kalynda K Gonzales; Yoland Smith
Journal:  Ann N Y Acad Sci       Date:  2015-04-15       Impact factor: 5.691

Review 9.  Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.

Authors:  Eva Schaeffer; Andrea Pilotto; Daniela Berg
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

10.  The nicotine-mediated decline in l-dopa-induced dyskinesias is associated with a decrease in striatal dopamine release.

Authors:  Tanuja Bordia; J Michael McIntosh; Maryka Quik
Journal:  J Neurochem       Date:  2013-03-03       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.